StockTipsArenaBeta

BUY Cohance Lifesciences Limited — Goldman Sachs

BUYCohance Lifesciences Limited
Cohance Lifesciences share price target & all analyst calls

byGoldman SachsHorizon: NA (inferred 1 year)6 Aug 2026via ET Now (Live)

Entry₹417.9Inferred
Target₹500
Total upside +19.65%
Stop lossNot given
CMP₹449.852d ago
Active+7.65%+11.15%upside left 10 mo left
Follow Goldman Sachs for new calls(100% target hit, 31 closed calls)Get alertsWatch COHANCE for new buy/sell callsGet alertsSee 3 other Long-term calls on COHANCESee 274 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 25 Oct, 9:35 pm IST
7 supporting5 neutral5 opposing
Supports the BUY call (7)

2 other SEBI-registered advisors have active long-term BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · same horizon·21 Oct · 4d ago

1 advisor has an active short-term BUY call on this stock

Advisor consensus · adjacent horizon·18 Aug · 2mo ago

Neutral / worth noting (5)

Mr. Abhimanyu Ojha has been appointed as the Chief Financial Officer of the company.

BSE · Company Update·9 Oct · 2w ago

(opens in new tab)

Mr. Abhimanyu Ojha has been appointed as the Chief Financial Officer of the company effective October 12, 2026.

NSE · Appointment·9 Oct · 2w ago

(opens in new tab)
Weighs against the BUY call (5)

Long-term trend bearish — 200-day average falling over the past quarter

Technicals · trend·23 Oct · 2d ago

1 other SEBI-registered advisor has an active long-term SELL call on this stock

Advisor consensus · same horizon·6 Aug · 3mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Cohance Lifesciences

All analyst calls on Cohance Lifesciences

More from Goldman Sachs

Every call and its outcome